Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$93.00 USD
+2.27 (2.50%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $93.00 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
BPMC 93.00 +2.27(2.50%)
Will BPMC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BPMC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BPMC
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
BPMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
Other News for BPMC
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Stifel Nicolaus Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
Blueprint Medicines price target raised by $10 at Stifel, here's why
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)